Twist Bioscience Corporation (TWST) Tops Q4 EPS by 16c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2020 Financial Results
November 23, 2020 7:01 AM EST-- Fiscal 2020 Revenues of $90.1M; Increase of 66% over $54.4M in Fiscal 2019 --
-- Strong Growth in Synthetic Biology, NGS Businesses --
-- Twist Biopharma Established 13 Partnerships, 8 with Milestones and/or Royalties in FY20 --
-- Expect Revenue of $110M to $118M for Fiscal 2021 --
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business... More
